Can-Fite BioPharma (CANF) Tops Q1 EPS by 19c

Can-Fite BioPharma (NYSE: CANF) reported Q1 EPS of $0.00, $0.19 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $196 thousand.

For earnings history and earnings-related data on Can-Fite BioPharma (CANF) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49
• Movano (MOVE) Misses Q2 EPS by 195c